NEWS & MEDIA · July 17, 2024
BioProcess Online: The path to producing an insulin biosimilar
This article summarizes coverage published on July 17, 2024.
About this coverage
BioProcess Online explored the practical challenges of bringing an insulin biosimilar from laboratory development to commercial-scale manufacturing. The feature included insights from rBIO co-founder Cameron Owen and chief scientific officer Dr. Deenadayalan Bakthavatsalam.
The discussion focused on production capacity, process design and the transition from pilot batches to larger output. It provides background on the manufacturing work behind rBIO’s insulin program.
This is an archived news summary; development plans described here reflect the original publication date.